Gyder Surgical announces first commercial surgical cases in the United States performed by Dr. Paul M. Lombardi, M.D., at the Tri-County Orthopedics’ Joint Replacement Institute outpatient center

NEWSROOM / /

The GYDER® Navigation System is the world’s first commercially available pin-less & image-less computer assisted technology for real time guidance during Total Hip Arthroplasty using the Anterior Approach February 22, 2026 11:05 ET  | Source: Gyder Surgical PALO ALTO, Calif. and MULGRAVE, Australia, Feb. 22, 2026 (GLOBE NEWSWIRE) — Gyder Surgical, a MedTech company specializing in intuitive, non-invasive orthopedic navigation […]

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults

NEWSROOM / /

February 20, 2026 14:43 ET  | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has accepted its New

Philips publishes its Annual Report 2025

NEWSROOM / /

February 19, 2026 04:00 ET  | Source: Royal Philips February 19, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025. Philips’ Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. The

Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services

NEWSROOM / /

Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients February 17, 2026 07:00 ET  | Source: Fortrea Holdings Inc DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced it has expanded its executive team. Oren

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

NEWSROOM / /

February 17, 2026 06:00 ET  | Source: Teva Pharmaceutical Industries Ltd Teva will hold an investor call and live webcast today,Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data. PARSIPPANY, N.J. and PARIS, Feb. 17, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE:

Sapu Bioscience Expands International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway

NEWSROOM / /

February 16, 2026 17:00 ET  | Source: Sapu Bioscience, LLC SAN DIEGO, CA, Feb. 16, 2026 (GLOBE NEWSWIRE) — Sapu Bioscience today announced advancements in its global IP portfolio supporting OT-101, its proprietary TGF-β antisense therapeutic platform, strengthening protection across neurology, oncology, and CNS drug delivery. Background on OT-101 OT-101 (TGF-β antisense inhibitor) is a

Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution

NEWSROOM / /

February 10, 2026 07:30 ET  | Source: Helus Pharma This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. BOSTON and TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) —  Helus PharmaTM (“Helus”)

Philips proposes to re-appoint CEO Roy Jakobs

NEWSROOM / /

February 10, 2026 00:55 ET  | Source: Royal Philips February 10, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Roy Jakobs is proposed to be re-appointed as its President/Chief Executive Officer and member of the Board of Management. The decision to propose the re-appointment of Roy Jakobs

Philips delivers full year 2025 with growth acceleration, strong margin expansion and solid cash flow; announces 2026-2028 targets at Capital Markets Day

NEWSROOM / /

February 10, 2026 01:00 ET  | Source: Royal Philips Amsterdam, February 10, 2026 Full year and Q4 highlights Capital Markets Day Roy Jakobs, CEO of Royal Philips:“In 2025, we delivered on our commitments as we scaled better care for more people. We strengthened our company while navigating a dynamic macro-environment. We ended the year with strong order

OPEN Health Announces Strategic Leadership Appointments to Strengthen Enterprise Growth and Decision Quality

NEWSROOM / /

February 09, 2026 04:00 ET  | Source: Open Health New York and London, Feb. 09, 2026 (GLOBE NEWSWIRE) — OPEN Health today announced senior leadership appointments that reinforce the company’s commitment to disciplined growth, enterprise alignment, and the company’s purpose of strengthening the decisions that shape care. As healthcare grows more complex, life-sciences organizations face

Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan

NEWSROOM / /

February 04, 2026 01:30 ET  | Source: Curium BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) — Curium Group today announced that together with PeptiDream Inc. and PDRadiopharma Inc., the first patient has been dosed in the companies’ registrational clinical trial of 177Lu-PSMA-I&T in Japan for patients with PSMA (*1)-positive metastatic castration-resistant prostate cancer (mCRPC). 177Lu-PSMA-I&T is a radiotherapeutic agent

Scroll to Top